Christopher Marai

Oppenheimer commented on CytRx Corporation (NASDAQ: CYTR) Tuesday and maintained an Outperform rating and $10 price target. The research note followed the company’s Q1 results and its posting EPS of $(0.31) versus expectations of $(0.20). Analysts Christopher Marai and Michelle Gilson...

With CytRx Corporation (NASDAQ: CYTR) shares up more than 35 percent in recent weeks, an analyst jumped on the bandwagon Friday, launching coverage with an Outperform rating. CytRx changed hands recently at $5.05, up 12.6 percent. The micro-cap drug development company published promising Phase II...

Christopher Marai of Oppenheimer on Thursday upgraded shares of ImmunoGen, Inc. (NASDAQ: IMGN) to Outperform from Perform with an $11 price target as recent weakness in shares following disappointing results from MARIANNE creates a buying opportunity given a "catalyst-rich" next 12 months. "We view...

In a report published Thursday, Oppenheimer analyst Christopher Marai reiterated an Outperform rating on Curis, Inc. (NASDAQ: CRIS), and raised the price target from $3.00 to $5.00. In the report, Oppenheimer noted, “Wednesday, Curis announced a collaboration with Aurigene Discovery Technologies to...

In a report published Tuesday, Oppenheimer analyst Christopher Marai initiated coverage on Aptose Biosciences (NASDAQ: APTO) with an Outperform rating and $17.00 price target. In the report, Oppenheimer noted, “Aptose is developing APTO-253, a targeted therapy for acute myelogenous leukemia (AML),...